Literature DB >> 3359231

The effect of cholinergic stimulation in the nucleus accumbens on locomotor behavior.

M C Austin1, P W Kalivas.   

Abstract

The present study was designed to investigate the effect of cholinergic stimulation of the nucleus accumbens (NA) on locomotor behavior. Microinjection of the cholinergic agonist, carbachol, into the NA resulted in a dose-dependent increase in spontaneous locomotor activity. Pretreating rats with the nicotinic antagonist, mecamylamine, significantly reduced the carbachol-induced locomotor response, whereas pretreatment with the muscarinic antagonist, atropine, was ineffective. Injection of the dopamine antagonist, haloperidol, prior to stimulation of the NA with carbachol, significantly attenuated the motor stimulant effect of carbachol. Evidence has accumulated to suggest that the increased locomotor response elicited from NA stimulation is mediated by GABAergic efferents from the NA to the substantia innominata (SI). Pretreatment with the GABA agonist, muscimol, into the SI significantly antagonized the locomotor hyperactivity induced by carbachol injection into the NA. Taken together, these data indicate that carbachol produces a motor stimulant effect by activating nicotinic receptors which may modulate the release of dopamine in the NA and inhibit the GABAergic efferents to the SI.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3359231     DOI: 10.1016/0006-8993(88)91400-x

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  14 in total

1.  Muscarine reduces inwardly rectifying potassium conductance in rat nucleus accumbens neurones.

Authors:  N Uchimura; R A North
Journal:  J Physiol       Date:  1990-03       Impact factor: 5.182

2.  Effect of acute and subchronic nicotine treatment on cortical efflux of [3H]-D-aspartate and endogenous GABA in freely moving guinea-pigs.

Authors:  L Beani; S Tanganelli; T Antonelli; L Ferraro; M Morari; P Spalluto; A Nordberg; C Bianchi
Journal:  Br J Pharmacol       Date:  1991-09       Impact factor: 8.739

3.  Participation of the cholinergic system of the dorsal and ventral striatum in the regulation of various forms of defense behavior.

Authors:  E V Pominova; K B Shapovalova
Journal:  Neurosci Behav Physiol       Date:  1995 Mar-Apr

4.  The features of the participation of the cholinergic mechanisms of the accumbens and caudate nuclei in the regulation of an instrumental defense reflex in dogs.

Authors:  K B Shapovalova; E V Pominova
Journal:  Neurosci Behav Physiol       Date:  1994 Sep-Oct

5.  Role of the striatal cholinergic system in the regulation of learned manipulation in rats.

Authors:  N M Dubrovskaya; I A Zhuravin
Journal:  Integr Physiol Behav Sci       Date:  1995 Apr-Jun

6.  Primary reinforcing effects of nicotine are triggered from multiple regions both inside and outside the ventral tegmental area.

Authors:  Satoshi Ikemoto; Mei Qin; Zhong-Hua Liu
Journal:  J Neurosci       Date:  2006-01-18       Impact factor: 6.167

7.  The participation of cholinergic systems of the nucleus accumbens in the differentiation of acoustic signals in dogs.

Authors:  K B Shapalova; E V Pominova
Journal:  Neurosci Behav Physiol       Date:  1993 Nov-Dec

Review 8.  Neurotransmitters and prefrontal cortex-limbic system interactions: implications for plasticity and psychiatric disorders.

Authors:  Alberto Del Arco; Francisco Mora
Journal:  J Neural Transm (Vienna)       Date:  2009-05-28       Impact factor: 3.575

9.  Selective loss of cholinergic neurons in the ventral striatum of patients with Alzheimer disease.

Authors:  S Lehéricy; E C Hirsch; P Cervera; L B Hersh; J J Hauw; M Ruberg; Y Agid
Journal:  Proc Natl Acad Sci U S A       Date:  1989-11       Impact factor: 11.205

10.  Blockade of NMDA receptors in the prefrontal cortex increases dopamine and acetylcholine release in the nucleus accumbens and motor activity.

Authors:  Alberto Del Arco; Gregorio Segovia; Francisco Mora
Journal:  Psychopharmacology (Berl)       Date:  2008-08-28       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.